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Abstract
Background: Pay for Performance (P4P) programs, based on provision of financial incentives for service quality,
have been widely adopted to enhance quality of care and to promote a more efficient use of health care
resources whilst improving patient outcomes. In Italy, as in other countries, the growing concern over the quality
of health services provided and the scarcity of resources would make P4P programs a useful means of improving
their performance. The aim of this paper is to evaluate whether it is possible to implement P4P programs in the
Lombardy Region, in Italy, based on the existing data set.
Methods: Thirteen quality measures were identified regarding four clinical conditions (acute myocardial infarction
(AMI), heart failure (HF), ischemic stroke and hip and knee replacement) on the basis of an international literature
review. Data was collected using the database of three institutions, which included hospital discharge records
(Scheda di Dimissione ospedaliera-SDO-) and letters of discharge. The study population was identified using both
the Principal ICD-9-CM diagnosis codes and the discharge date. A Statistical Analysis System (SAS) program was
used for the text analysis.
Results: It was possible to calculate almost all the parameters pertaining to the three hospitals as all the data
required was available with the exception of inpatient mortality in two hospitals and smoking cessation advice/
counseling in one hospital.
Conclusions: On the ground of this analysis, we believe that it is possible to implement a P4P program in the
Lombardy Region. However, for this program to be initiated, all necessary data must be available in electronic
format and uniformly collected. Moreover, several other factors must be assessed: which clinical conditions should
be included, the threshold for each quality parameter, the amount of financial incentives offered and how they will
be provided.
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Background
Escalating costs and the growing imbalance between
primary and specialty care, have highlighted the urgent
need for a deep reform of the health care payment
system. One of the core problems of the existing system
is that the dominant fee-for-service model rewards
volume and intensity rather than value and quality of
care. Although the faults of the existing healthcare
payment system are evident, there is great uncertainty
as to which approach would achieve the best results[1].
In the United States of America (USA), performance
based remuneration programs ("Pay for Performance"-
P4P) for general practitioners and hospitals have been
experimentally introduced since 2001, in an effort to
better reward service quality[2].
Earlier this decade, pay for performance (P4P)
programs took center stage as a tactic for realigning
payment with value. P4P programs aim to overcome the
limits of the fee-for-service model based on DRG (Diag-
nosis Related Group) fixed rate remuneration, by paying
extra for the implementation of specific processes/
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types of information are required for the correct opera-
tion of a P4P program. These include health process
and outcome measures that can be positively influenced
by clinical management and information about specific
treatments and clinical services that can improve an
individuals’ poor health status (health production
function)[3].
The P4P initiative in healthcare management is based
on the concept of fostering and rewarding improvement
in this sector. Most P4P programs are designed to
promote value-based health care, defined as a more effec-
tive distribution of funds and efforts through measure-
ment, transparency and accountability[4]. The basic idea
behind this initiative is to provide healthcare providers
with financial incentives to achieve specific quality stan-
dards[5]. In other words, this payment model rewards
physicians, hospitals, medical groups and other health-
care providers for meeting certain quality and efficiency
performance measures, which the providers and purcha-
sers have previously agreed in writing.
T h ep o p u l a r i t yo fP 4 Pp r o g r a m sc a nb ea t t r i b u t e dt o
the desire to explore new payment methods that can
improve quality and reduce costs, based on the hypoth-
esis that, in healthcare, as in other industries, higher
quality equals lower cost[6]. In healthcare, the relation-
ship between high quality and low cost has yet to be
fully demonstrated. The ultimate goal of P4P reforms is
to provide evidence-based care and to ensure that pro-
cess management is supplemented by patient-reported
outcome measures[7]. In the early 1970s, the British epi-
demiologist Archie Cochrane considered that, because
of limited societal resources, only healthcare services
shown to be effective should be provided to patients[8].
P4P is increasingly used to improve healthcare quality
and safety[9]. More than half of all commercial health
m a i n t e n a n c eo r g a n i z a t i o n si nt h eU S Ae m p l o yaP 4 P
program, and approximately 40 P4P programs focus
specifically on inpatient hospital care[10,11]. P4P has
been implemented in other countries (for instance, P4P
incentives were introduced in the UK for primary care
in 1991[12]) and more countries are considering their
introduction. As was the case with the DRG and quality
certification systems, there is reason to believe that P4P
programs will eventually be introduced in Italy as well.
The purpose of this paper is to evaluate whether data
and conditions for the implementation of P4P programs
exist in Lombardy, in the north of Italy. We focused our
attention on inpatient hospital care.
Methods
Based on an international literature review (done through
a search in PubMed of the terms: P4P, quality program,
outcome, payment), thirteen quality parameters were
identified regarding four clinical conditions: acute
myocardial infarction (AMI), heart failure (HF), ischemic
stroke and hip and knee replacement (table 1)[1,3,9,
10,13-23]. Data on these thirteen parameters were avail-
able in electronic format.
Data were collected from three public hospitals of
national interest. We chose these three hospitals from
over one hundred other options in the Lombardy
R e g i o nb e c a u s et h e yw e r et h ef i r s tt oc o m p l yw i t ha l l
the IT standards set by the Regional Health Authority.
Therefore, these three hospitals are not representative of
the health structure in the entire Region of Lombardy,
but were selected because they already reached the IT
standard that all hospitals will be expected to achieve in
the near future. Data sources include two formal statu-
tory documents available in electronic format: hospital
discharge records (Scheda di Dimissione ospedaliera-
SDO-) and letters of discharge. It is important to assess
whether the quality controls carried out by the Region
of Lombardy show that the coding method employed in
the three hospitals is accurate (i.e. giving patients a diag-
nosis) and that physicians attend mandatory training
courses for completing letters of discharge.
No ethical approval is required for this study accord-
ing to the Italian law 196/2003 and according to Regola-
mento Regionale Lombardo n.9, july 2006 (BURL n.29,
II suppl. Ord. 21/07/2006); the study only involved the
use of anonymized data already available at the
hospitals.
The study population was identified using two data
elements: the Principal ICD-9-CM diagnosis codes and
the discharge date. All patients discharged in 2008 were
considered eligible. Patients who died while in hospital
were excluded from all measurements, with the excep-
tion of inpatient mortality. In addition, nonsmokers and
former smokers were excluded from the “smoking cessa-
tion counseling” measure.
Measures are expressed as the number of times a
selected procedure (i.e. Beta-blockers at discharge) was
performed in eligible patients at a selected hospital,
divided by the total number of patients eligible for that
procedure and treated at that hospital. In order to ascer-
tain whether a selected procedure has been performed
in eligible patients, a list of key words was devised for
each measure and a search was performed on the letters
of discharge. For instance, in order to find out the
percentage of patients with AMI who were prescribed
beta-blockers at discharge, a list of beta-blockers agents
was created, including both active pharmaceutical ingre-
dients and trade names, together with employed abbre-
viations and acronyms. These words were searched for
in all letters of discharge.
The Statistical Analysis System (SAS) program, and, in
particular, Base SAS Software, were used for the text
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function, which searches for a text string inside a data-
base, has been employed. The “upcase” function was
used to include both upper and lower case text.
The results obtained from the automatic search per-
formed on the letters of discharge were then checked
manually and ratings of “true/false positive” and of “true/
false negative” assigned. Finally, the sensitivity and specifi-
city of the method were calculated. [Sensitivity = number
of true positives/(sum of true positives + false negatives);
Specificity = number of true negatives/(sum of true
negatives + false positives)].
Results
The number of patients included in the different
analyses of hospital performance on process measures is
shown in Table 2.
The results for each measure are summarized in Tables
3 and 4. There is missing data for hospitals n. 2 and n. 3
in the inpatient mortality measure and for hospital n. 2
in the adult smoking cessation advice/counseling
measure. Mortality rate data was not available, while it
was not possible to calculate the rate in adult smoking
cessation advice/counseling data because the structure of
the letter of discharge electronic format did not allow us
to identify smokers among eligible patients or smoking
cessation advice in discharge recommendations.
The sensitivity and specificity of the method, for each
measure analyzed, are summarized in Table 5. Specifi-
city ratings reached 100% in the majority of cases,
meaning that the test effectively excluded all negative
readings (i.e. if beta-blockers are mentioned, they were
certainly referred to in the letter). As for sensitivity,
though the ratings did not always reach 100%, scores
were considered acceptable as sensitivity values always
exceeded 90%, with the exception of former smokers in
patients with HF and LDL cholesterol admitted at
hospital n.3.
Discussion and Conclusions
The aim of this paper is to evaluate whether data and
conditions for the implementation of P4P programs
exist in the Region of Lombardy, Italy. Three hospitals
of national interest were chosen as sites where 13 out-
come measures relating to four clinical conditions have
been evaluated. This set of indicators was chosen since
it was considered to be reasonably applicable to hospi-
tals in the Region of Lombardy.
In order to better assess the results obtained, several
specific considerations should be made for a number of
indicators used in the evaluation:
- Aspirin prescribed at discharge: results had shown
that the drug was prescribed at discharge in more
than 80% of cases of AMI. However, it is possible
that discharge records that do not include the pre-
scription of this drug, relate to patients who were
already on anticoagulation therapy.
- Beta-blocker prescribed at discharge: beta-blockers
were prescribed at discharge in more than 65%
of cases of AMI in all three hospitals. The data
must be assessed taking into account the relative
contraindications associated with the use of beta-
blockers. There are many contraindications including
asthma and reversible airway obstruction in pati-
ents with respiratory diseases, atrioventricular con-
duction disturbances, severe bradycardia, Raynaud’s
Table 1 Quality measures (n = 13) and clinical conditions
(n = 4) used in the present study.
Clinical Conditions Measures
Acute Myocardial
Infarction (AMI)
1. Aspirin prescribed at discharge
2. Beta-blocker prescribed at discharge
3.Adult smoking cessation advice/counseling
4. LDL cholesterol assessment
5.Lipid lowering therapy at discharge
6. Inpatient mortality
Heart Failure (HF) 7.Evaluation of left ventricular systolic (LVS)
function (LVF Assessment)
8. ACEI or ARB for left ventricular systolic
dysfunction (LVSD)
9. Adult smoking cessation advice/counseling
Ischemic Stroke 10. Thrombolytic therapy administered
11. Discharged on cholesterol reducing
medication
12. Smoking cessation advice/counseling
Hip and Knee
Replacement
13.Recommended Venous Thromboembolism
(VTE) Prophylaxis Ordered
Table 2 Number of patients included in the analyses of hospital performance on process measures.
AMI HF Ischemic Stroke Hip/Knee Replacement
Patients Letters of
discharge
Patients Letters of
discharge
Patients Letters of
Discharge
Patients Letters of
Discharge
Hospital N.1 498 460 1590 1590 347 347 182 182
Hospital N.2 557 345 1761 1277 572 420 533 533
Hospital N.3 325 305 575 575 172 172 200 200
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Hospital N.1 Hospital N.2 Hospital N.3
N. of times the selected
procedure is performed
in eligible patients
N. of
eligible
patients
N. of times the selected
procedure is performed
in eligible patients
N. of
eligible
patients
N. of times the selected
procedure is performed
in eligible patients
N. of
eligible
patients
1. Aspirin prescribed at
discharge
390 460 323 345 262 305
2. Beta-blocker prescribed
at discharge
376 460 249 345 200 305
3. Adult smoking cessation
advice/counseling
16 139 2 46
4. LDL cholesterol
assessment
73 460 48 345 1 305
5. Lipid lowering therapy at
discharge
376 460 256 345 219 305
6. Inpatient mortality 38 498
7. Evaluation of left
ventricular systolic (LVS)
function (LVF Assessment)
1049 1590 663 1277 314 575
8. ACEI or ARB for left
ventricular systolic
dysfunction (LVSD)
1059 1590 909 1277 352 575
9. Adult smoking cessation
advice/counseling
22 145 6 33
10. Thrombolytic therapy
administered
15 347 6 420 0 172
11. Discharged on
cholesterol reducing
medication
74 347 174 420 37 172
12. Smoking cessation
advice/counseling
43 3 81 0
13. Recommended Venous
Thromboembolism (VTE)
Prophylaxis Ordered
169 182 0 533 24 200
Table 4 Results for each measure.
Measures Hospital N.1 Hospital N.2 Hospital N.3
1. Aspirin prescribed at discharge 84.8% 93.6% 85.9%
2. Beta-blocker prescribed at discharge 81.7% 72.2% 65.6%
3 Adult smoking cessation advice counseling. 11.5% 4.3% 4.3%
4. LDL cholesterol assessment 15.9% 13.9% 0.3%
5. Lipid lowering therapy at discharge 81.7% 74.2% 71.8%
6. Inpatient mortality 7.6%
7. Evaluation of left ventricular systolic (LVS) function (LVF Assessment) 66.0% 51.9% 54.6%
8. ACEI or ARB for left ventricular systolic dysfunction (LVSD) 66.6% 71.2% 61.2%
9. Adult smoking cessation advice counseling 15.2% 18.2% 18.2%
10. Thrombolytic therapy administered 4.3% 1.4% 0.0%
11. Discharged on cholesterol reducing medication 21.3% 41.4% 21.5%
12. Smoking cessation advice/counseling 12.1% 80.0%
13. Hip or Knee replacement Patients with Recommended Venous Thromboembolism
(VTE) Prophylaxis Ordered
92.9% 0.0% 12.0%
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A manual check of the files revealed that in many
cases in which beta-blockers were not prescribed,
patients were already receiving beta-agonists treat-
ment for respiratory diseases.
- Lipid lowering therapy at discharge: the list of
drugs used for the calculation of the indicator
included all the active pharmaceutical ingredients
used to lower blood lipids (triglycerides and/or
cholesterol) and improve lipid profile (increased
HDL cholesterol). However, a more stringent selec-
tion of active ingredients would be necessary for a
more specific goal (eg reduction of LDL choles-
terol). In any case, the indicator should be assessed
taking into account that no distinction has been
made between AMI types. A better level of accu-
racy would be guaranteed by identifying AMI
patients who are hyperlipidemic and limiting the
lipid lowering therapy assessment to this specific
sub-group.
- Thrombolytic therapy: the available data did not
allow the selection of ischemic stroke patients
who were eligible for thrombolytic therapy. Therefore,
all patients diagnosed with ischemic stroke were
considered eligible. In the perspective of introducing a
P4P program this assumption should be modified.
In summary, since this was a first attempt of calcula-
tion, a simple, although less accurate measuring system
was applied. Adjustments would be required if a P4P
system was implemented in the Region of Lombardy.
The results obtained for each measure can be consid-
ered a starting point for the target definition. In order to
implement a P4P program, it is necessary to determine
which level of performance will merit a financial incen-
tive. However, at present, this decision is made difficult
b yt h ec o n s i d e r a b l ev a r i a b i l i t yi nt h ep e r f o r m a n c eo ft h e
three hospitals.
It would be interesting to compare the performance of
these three hospitals with the averages obtained for other
health systems, but this is not the aim of the study.
Furthermore, in order to make this comparison we
would need to define the selection criteria of the patient
group studied and all hospitals must have electronic data
available.
Electronic data sources were used (i.e. letters of
discharge). Hard copy data sources were not considered
in the present evaluation due to the additional cost
Table 5 Sensitivity and specificity of the method used.
Hospital N.1 Hospital N.2 Hospital N.3
Sensibility Specificity Sensibility Specificity Sensibility Specificity
1. Aspirin prescribed at discharge 96.1% 100.0% 99.7% 100.0% 97.8% 100.0%
2. Beta-blocker prescribed at discharge 95.7% 100.0% 97.6% 100.0% 100.0% 100.0%
3. Adult smoking cessation advice
Counseling
100.0%
(68.9% for the
research of Former
smokers)
100.0% 100.0%
(100.0% for the
research of former
smokers)
100.0%
4. LDL cholesterol assessment 100.0% 100.0% 100.0% 100.0% 33.3% 100.0%
5. Lipid lowering therapy at discharge 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
6. Inpatient mortality 100.0% 100.0%
7. Evaluation of left ventricular systolic
(LVS) function (LVF Assessment)
99.0% 100.0% 100.0% 100.0% 100.0% 100.0%
8. ACEI or ARB for left ventricular
systolic dysfunction (LVSD)
100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
9. Adult smoking cessation advice
counseling
96.3% (94.5% for the
research of former
smokers)
100.0% 100.0% (73.3% for the
research of former
smokers)
100.0%
10. Thrombolytic therapy administered 100.0% 100.0% 100.0% 99.5% 100.0% 100.0%
11. Discharged on cholesterol reducing
medication
100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
12. Smoking cessation advice/
counseling
100.0% (100.0% for
the research of
former smokers)
100.0% 100.0% 97.6% (100.0% for the
research of former
smokers)
13. Hip or Knee replacement Patients
with Recommended Venous
Thromboembolism (VTE)
Prophylaxis Ordered
99.4% 100.0% 100.0% 100.0% 100.0% 100.0%
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program measures needs to be easily accessible. All
three chosen hospitals had letters of discharge in elec-
tronic format. In the course of the evaluation, it became
apparent that not all the information required for the
selected measures was available in the letters of dis-
charge. Data on venous thromboembolism prophylaxis
was not reported by one of the three hospitals analyzed.
In addition, there is indication that several letters were
incomplete; for example, only 46 patients with AMI and
10 patients with ischemic stroke admitted to hospital n.
3 were reported as smokers. This information gap may
be due to the fact that until now these details were
never requested or subject to evaluation. As has been
the case in the USA, the introduction of a P4P program
is likely to result in rapid improvement in the reporting
of these measures, primarily thanks to improved docu-
mentation of clinical activities [10,21-23,25-27]. Clinical
data will continue to be difficult to obtain, especially in
the absence of widespread use of electronic record
supports, but the measurement may offer the opportu-
nity to train physicians to comply with guidelines and to
document their work better.
During the past decade, the use of hospital-based P4P
programs to improve quality, has largely expanded.
However, few programs were systematically evaluated,
leaving several substantial gaps in the knowledge of
their effectiveness [9,28]. First, the clinical conditions
used as a basis for P4P systems have so far been limited
to cardiovascular disease, pneumonia, hip and knee
replacement and few others. Therefore, there is virtually
no knowledge about the effects of P4P incentives
applied to other conditions. Second, the effect of differ-
ent types of incentives used in hospital P4P programs is
unknown. Third, there is little evidence to assess the
effect of P4P programs on quality. Fourth, it is yet
unknown whether the quality improvements resulting
from hospital P4P programs outweigh their cost.
This paper demonstrates that a P4P program could be
feasible in the Region of Lombardy. However, solid
electronic information systems should be put in place in
order to contain implementation costs and to enable the
rapid and effective calculation of measures. All physi-
cians in hospitals must be trained to select patients data
correctly, which they have to enter in the patient’se l e c -
tronic records. The data obtained from the three hospi-
tals we studied, where this process has started, shows
good results, the data entered and its quality may allow
Regional Health Authorities to implement this program.
In conclusion, all data necessary for P4P programs
should be available in electronic format and uniformly
collected before these programs are introduced. Several
other factors that should be clarified prior to imple-
menting P4P programs in the Region of Lombardy and
subsequently in Italy, include: which clinical conditions
should be included, the threshold for each quality
measure, the amount of financial incentives offered and
how they will be provided.
No ethical approval was necessary because the study
only involved anonymized data available on request
from each hospital.
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